ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate at the World Vaccine Congress Washington being held in Washington, D.C. April 14-17, 2019. Teri Heiland, Ph.D., Immunomic’s Senior Vice President of Research and Development, will participate in a panel entitled “Strategies to enhance vaccine acceptance in future generations.”
In addition to its panel participation, Immunomic has been nominated for the World Vaccine Congress Vaccine Industry Excellence (ViE) Award for Best New Vaccine Technology/Platform. The winner of the award is expected to be announced during the conference.
The World Vaccine Congress Washington is a multi-faceted conference experience with over 300 industry leading speaker, 10 conferences, 8 workshops, 100+ exhibitors providing the most exciting vaccine event on the planet.
Panel details are as follows:
Title: Strategies to enhance vaccine acceptance in future
generations
Panel Category: Vaccine Safety
Panel
Date and Time: Tuesday, April 16, 2019 9:40 AM
Location: Renaissance
Washington DC Downtown Hotel, Washington D.C.
About UNITE
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI’s UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.